Future OncologyVol. 11, No. 14 CommentaryThe discipline of onco-cardiologyElie MouhayarElie Mouhayar*Author for correspondence: E-mail Address: emouhayar@mdanderson.org Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 1515 Holcombe Boulevard, Unit 1451, Houston, TX 77030-4009, USASearch for more papers by this authorPublished Online:22 Jul 2015https://doi.org/10.2217/fon.15.71AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancer survivorscardiotoxicityonco-cardiologytargeted therapytyrosine kinase inhibitorsvascular toxicityReferences1 Siegel R, Desantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62(4), 220–241 (2012).Crossref, Medline, Google Scholar2 Ning Y, Shen Q, Herrick K et al. Cause of death in cancer survivors (abstr). Cancer Res. 72, Abstract LB339 (2012).Google Scholar3 McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-AKT signaling. Blood 124(25), 3829–3830 (2014).Crossref, Medline, CAS, Google Scholar4 Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-ERBB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105(13), 1551–1554 (2002).Crossref, Medline, CAS, Google Scholar5 Zhang S, Liu X, Bawa-Khalfe T et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18(11), 1639–1642 (2012).Crossref, Medline, Google Scholar6 Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N. Engl. J. Med. 369(19), 1779–1781 (2013).Crossref, Medline, CAS, Google Scholar7 Gao R, Zhang J, Cheng L et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol. 55(18), 1907–1914 (2010).Crossref, Medline, CAS, Google Scholar8 Oliveira GH, Dupont M, Naftel D et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the intermacs registry (interagency registry for mechanically assisted circulatory support). J. Am. Coll. Cardiol. 63(3), 240–248 (2014).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByCardio-oncology: a special focus issue from Future OncologyRobin L Jones & Maria Teresa Sandri22 July 2015 | Future Oncology, Vol. 11, No. 14 Vol. 11, No. 14 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 78 times History Published online 22 July 2015 Published in print July 2015 Information© Future Medicine LtdKeywordscancer survivorscardiotoxicityonco-cardiologytargeted therapytyrosine kinase inhibitorsvascular toxicityFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download